353 pharmaceutical stock market value list out: the first 600 billion market value of pharmaceutical stocks were born, 癀, people blessed ... 54 doubled

Time flies, and in a blink of an eye 2020 has passed.
the last trading day of 2020, the three major A-share indexes rose collectively, with the Shanghai index up nearly 14 per cent, the Shenzhen index up nearly 39 per cent and the GEM index up nearly 65 per cent.
pharmaceutical stocks, as of the close of december 31, 2020, Hengrui Pharmaceuticals, Meirui Medical, Pharmaceutical Mingkangde, Zhifei Bio, Changchun Gaoxin, Chipaiand other 11 pharmaceutical stock markets are worth 100 billion dollars.
, Hengrui Pharmaceuticals became the first pharmaceutical stock with a market capitalization of more than 600 billion yuan on December 25;
From the point of view of the rise and fall, there are 54 pharmaceutical stock market value doubled, Wantay Bio, Anglo Medical, Kantai Medical rose more than 10 times;
it is worth mentioning that the market value of thehas soared by nearly 100 billion yuan so far this year, surpassing Yunnan white medicine and becoming the market value leader of the Chinese medicine sector.
11 hundred billion market capitalization pharmaceutical companies leading pharmaceutical stocks! On the last trading day of 2020, the top 600 billion pharmaceutical stocks by market capitalisation rose collectively, with the Shanghai index rising nearly 2 per cent to its highest level since February 2018, the Shenzhen index rising nearly 2 per cent to its highest level since July 2015 and the GEM index rising more than 2 per cent to its highest level since July 2015.
's full-year performance, the Shanghai index rose nearly 14%, the Shenzhen index rose nearly 39%, and the GEM index rose nearly 65%.
2020 is the big year for pharmaceutical stocks, in the face of the sudden new crown epidemic, the pharmaceutical industry has become the focus of the public, collection, medical insurance catalog adjustment and a series of policies, such as the introduction and landing, to further promote the development and transformation of the industry.
as of the close of trading on December 31, 2020, the stock market value of 11 pharmaceutical stocks, such as Hengrui Pharmaceuticals, Meirui Medical, Pharmaceutical Mingkangde, Zhifei Bio, Changchun Gaoxin, Andai , was worth 100 billion yuan.
Hengrui Pharma firmly held the position of "pharmaceutical stock brother" and became the first pharmaceutical stock with a market value of more than 600 billion yuan, an increase of more than 200 billion yuan compared with a year ago.
addition, The market capitalisation of Murray Healthcare has exceeded $500 billion.
note that there will be only five pharmaceutical stocks with a market capitalisation of 100 billion in 2019.
: On December 25, 2020, Hengrui Pharmaceuticals' market capitalization passed the 600 billion yuan mark.
review of Hengrui Pharmaceuticals' market capitalization development, from listing to exceeding the market value of 100 billion yuan, it took 16 years; In June 2020, it broke through the market value of 300 billion yuan, and four months later, it broke through the 400 billion yuan mark, and in June 2020, it exceeded the market value of 500 billion yuan, and by the close of trading on December 31st, it had a market value of 594.3 billion yuan.
recently, recently, the high-profile 2020 National Health Care Directory negotiations results came out, Hengrui Pharmaceuticals announced that the company's products injected with kariliju monoanti, hydrochloric acid ascetamine injection and pemendonase injection negotiations successfully, incorporated or retained in the "National The scope of category B of the Medical Insurance Directory, the agreement is valid from March 1, 2021 to December 31, 2022, injection of yew alcohol (albumin binding type) as the second batch of national organization drugs centralized procurement of the selected drugs, included in the National Health Insurance Directory B scope.
, said the four products are included in the National Health Insurance Directory, will be conducive to product sales.
four products will have total sales of about 3.2 billion yuan in 2019 and about 4.8 billion yuan in the first three quarters of 2020.
There are brokerage analysis pointed out that Hengrui pharmaceutical innovation pipeline is rich, has entered at least one new varieties approved each year to be approved for listing of the virtuous cycle, become the main driving force for performance growth, in the next three years in addition to the original new varieties continue to release, there are new diabetes drugs, sea curvapa ethanolamine, fluorine parri and so on are expected to be listed.
Meri Healthcare: In October 2018, Myer Medical landed on A-shares, with a market capitalization of more than 200 billion yuan a year after its listing, and by the close of trading on December 31, 2020, it had a market capitalization of 517.9 billion yuan, making it the second largest pharmaceutical company after Hengrui Pharmaceuticals.
the first three quarters of 2020, Myer Medical revenue was RMB16.06 billion, up 29.76 percent year-on-year, and net profit was RMB5,363 million, up 46.09 percent year-on-year.
Mari Medical said that into the third quarter, affected by the continued global spread of the new crown epidemic, the international market demand for related anti-epidemic products such as monitors, ventilators, infusion pumps, new crown antibody reagents and other high levels;
the same time, the company continued to strengthen internal management, improve operating efficiency, during the outbreak using online promotion and other means of marketing promotion, travel expenses and other operating expenses can be effectively controlled, net profit continued to grow strong.
In addition, the international market demand for anti-epidemic products is still large, and in order to cope with the second wave of the epidemic, some countries have begun to prepare to increase the deployment of medical system construction, in addition to the gradual recovery of conventional business, in order to prevent the outbreak of secondary outbreaks and strengthen the construction of major epidemic treatment capacity, all over the country has also launched a medical replacement board planning, the company will usher in better development opportunities.
expects the company's operating income to be RMB19.87 billion to RMB21.52 billion in 2020, up 20% to 30% YoY, and net profit of RMB6.08 billion to RMB6.55 billion, up 30% to 40% YoY.
54 medicines doubled in value! These three jumped more than 10 times, the tabletsinto the "Chinese medicine stocks of a brother" rose more than 100% of the pharmaceutical stocks from the rise and fall, there are 54 pharmaceutical companies doubled in market value, of which, Wantay Bio, Yingke Medical, Kantai Medical rose more than 10 times;
it is worth mentioning that the market value of thehas soared by nearly 100 billion yuan so far this year, surpassing Yunnan white medicine and becoming the market value leader of the Chinese medicine sector.
: In June 2020, the market value exceeded the 100 billion yuan mark, and as of December 31, the market value was 161.4 billion yuan, an increase of nearly 100 billion yuan so far this year.
data show that as early as 2014, thebegan to implement the "one nuclear two wings" big health development strategy, on the basis of solid pharmaceutical manufacturing industry, strengthen cosmetics, daily chemical products and health care products, health food wings, and at the same time expand the pharmaceutical circulation industry to supplement.
years of careful construction and development, the company basically formed a health field multi-industry gathering pattern, product structure is constantly optimized.
2020, is a key year under the development strategy of the film, the company will strengthen the brand, capital, scientific research and other "hard core" role, to promote the project inspection year, fine management promotion year, the national civilized units strive for the year, the whole brand marketing year as a grasping hand, enhance the advantages of the board, strengthen industrial integration and mergers and acquisitions, continue to promote market value and brand value conversion efficiency, to achieve 2020 development to a new level.
the first three quarters of 2020,revenue was RMB5,070 million and net profit was RMB1,329 million, up more than 15% year-on-year.
: April 29, 2020 landed on the Shanghai Stock Exchange, 26 consecutive one-word board, becoming the largest number of new pharmaceutical plates so far this year.
market capitalisation of 87.4 billion yuan, up more than 20 times as much as it closed on December 31.
data show that Wante Bio's main business has in-body diagnostic reagents, in-body diagnostic equipment and vaccine research and development, production and sales, core products include HIV diagnostic reagents, viral hepatitis series diagnostic reagents.
, Wantay Bio announced that the company and Xiamen University, the University of Hong Kong in cooperation with the development of the nasal influenza virus vector new crown pneumonia vaccine, has entered the second phase of clinical trials, phase II clinical trials by the Jiangsu Provincial Center for Disease Control and Prevention responsible for the implementation of the trial has been approved by the Jiangsu Provincial Center for Disease Control and Prevention Ethics Committee approved the start.
pharmaceutical stock market value at a glance